The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy – A case series and review of the literature

• Main Authors: Catherine Tang, David J. Rabbolini, Marie‐Christine Morel‐Kopp, David E. Connor, Philip Crispin, Christopher M. Ward, William S. Stevenson
• Format: Article
• Language: English
• Published: Wiley 2020-01-01
• Series: Research and Practice in Thrombosis and Haemostasis
• Subjects: familial platelet disorder; familial platelet disorder with predisposition to myeloid malignancy; hereditary myeloid malignancy; inherited thrombocytopenia; RUNX1
• Online Access: https://doi.org/10.1002/rth2.12282

Abstract Germline mutations of runt‐related transcription factor‐1 (RUNX1) cause familial platelet disorder with predisposition to myeloid malignancy (FPDMM), most commonly associated with thrombocytopenia and propensity to develop myeloid neoplasms. A key clinical question is which patients with a family history of thrombocytopenia should undergo genetic testing for RUNX1 mutations. Typically, molecular diagnosis by genetic sequencing is performed when the clinical phenotype is suggestive of this diagnosis; however, our understanding of the spectrum of associated features suggestive of this diagnosis continues to evolve. Herein, we report a case series of 3 unrelated families with RUNX1‐associated FPDMM and clinical phenotypes not typically reported with this condition. These cases expand our understanding of FPDMM and highlight the complexity of transcriptional regulation of hematopoiesis and its potentially diverse phenotypes. We describe our approach to diagnosis and management of these individuals and the importance of long‐term surveillance in these cases.